MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech’s leadership team will provide an overview of the Company’s strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via t ...

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EST (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. ...

Core Insights - BioNTech SE, in collaboration with InstaDeep Ltd., will host its second AI Day on October 1, 2025, in London, focusing on BioNTech's AI strategy and its applications in the company's pipeline and internal processes [1] Company Overview - BioNTech is a global biopharmaceutical company specializing in next-generation immunotherapy, developing innovative therapies for cancer and serious diseases [3] - The company utilizes a variety of computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals [3] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and CAR T cell therapies [3] - The company is also researching multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [3] - BioNTech has established partnerships with several global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Roche Group [3]

Core Viewpoint - BioNTech SE will announce its financial results for the second quarter of 2025 on August 4, 2025, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Group 1: Financial Results Announcement - The financial results for Q2 2025 will be disclosed on August 4, 2025 [1]. - A conference call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day [1]. Group 2: Accessing the Conference Call - Participants can register for the live conference call via a provided link, with dial-in numbers and a PIN sent post-registration [2]. - It is recommended to register at least one day in advance for the call [2]. - The slide presentation and audio of the webcast will be accessible through a specified link [2]. Group 3: Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4]. - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [4]. - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies [4]. - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [4]. - BioNTech has established collaborations with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech [4].

Core Points - BioNTech SE announced the resignation of Ryan Richardson as Chief Strategy Officer effective September 30, 2025, to pursue new professional opportunities [1] - Richardson joined BioNTech in 2018 and has been instrumental in raising over USD 1 billion through various financing activities, including the Initial Public Offering on Nasdaq [2] - His contributions include building Global Strategy and Corporate Development functions, enhancing Capital Markets and Investor Relations, and serving on the Board of Directors of InstaDeep Ltd. since its acquisition in 2023 [2] Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases [4] - The company has a diversified oncology product portfolio, including mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies [4] - BioNTech collaborates with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech, to advance its research and development efforts [4]

Core Points - BioNTech SE will announce its financial results for Q1 2025 on May 5, 2025, and will host a conference call and webcast at 8:00 a.m. EDT [1] - The conference call will be accessible via telephone registration, and participants are encouraged to register at least one day in advance [2] - A replay of the webcast will be available shortly after the call and archived for 30 days on the company's website [3] Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4] - The company utilizes a variety of computational discovery and therapeutic drug platforms for rapid biopharmaceutical development [4] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, targeted therapies like antibody-drug conjugates (ADCs), and CAR T cell therapies [4] - The company is also developing multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and manufacturing [4] - BioNTech has established collaborations with various global pharmaceutical companies, including Pfizer, Genentech, and Regeneron [4]